Liver Pathology Related to Onco-Therapeutic Agents

Paige H Parrack; Stephen D Zucker; Lei Zhao

doi:10.1016/j.path.2023.04.006

Liver Pathology Related to Onco-Therapeutic Agents

Surg Pathol Clin. 2023 Sep;16(3):499-518. doi: 10.1016/j.path.2023.04.006. Epub 2023 Jun 11.

Authors

Paige H Parrack¹, Stephen D Zucker², Lei Zhao³

Affiliations

¹ Department of Pathology, Brigham and Women's Hospital, 75 Francis street, Boston, MA, 02115, USA; Harvard Medical School.
² Harvard Medical School; Department of Medicine, Brigham and Women's Hospital, 75 Francis street, Boston, MA, 02115, USA.
³ Department of Pathology, Brigham and Women's Hospital, 75 Francis street, Boston, MA, 02115, USA; Harvard Medical School. Electronic address: lzhao19@bwh.harvard.edu.

PMID: 37536885
DOI: 10.1016/j.path.2023.04.006

Abstract

Oncotherapeutic agents can cause a wide range of liver injuries from elevated liver functions tests to fulminant liver failure. In this review, we emphasize a newer generation of drugs including immune checkpoint inhibitors, protein kinase inhibitors, monoclonal antibodies, and hormonal therapy. A few conventional chemotherapy agents are also discussed.

Keywords: Antibody–drug conjugate; Checkpoint inhibitor; Hepatotoxicity; Hormonal therapy; Liver; Monoclonal antibody; Protein kinase inhibitor; Tyrosine kinase inhibitor.

Publication types

Review

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antineoplastic Agents* / adverse effects
Humans
Liver

Substances

Antineoplastic Agents
Antibodies, Monoclonal